Product
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody
Aliases
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
1 clinical trial
2 indications
Indication
DermatitisIndication
AtopicClinical trial
A Phase Ib/II Study to Evaluate the Safety, Pharmacokinetic and Efficacy of Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) in Chinese Children and Adolescents (6 Years Old ≤ Age <18 Years Old) With Moderate to Severe Atopic DermatitisStatus: Not yet recruiting, Estimated PCD: 2024-08-01